EMA Wants to Know if Pharma is Ready for Brexit
The agency is sending a survey out to pharmaceutical companies in the UK to gain information on their preparedness for Brexit.
The European Medicines Agency announced on Jan. 23, 2018 that it was performing a survey to see if pharmaceutical companies are ready for the United Kingdom’s withdrawal from the European Union, also known as Brexit. The survey will also ask companies to identify any concerns they may have.
Specifically, EMA plans to use the survey to identify companies that may need help addressing concerns that have risen from Brexit. EMA and the European Commission will also use survey results to plan for needed resources. The agency hopes the survey may also urge companies that have not yet taken action regarding Brexit-related issues to start doing so.
The survey is being sent to marketing authorization holders located in the UK, or companies who have quality control, batch release, and/or import manufacturing sites or a qualified person for pharmacovigilance (QPPV) or pharmacovigilance system master file (PSMF) in the UK. Companies will be asked about their plans to submit transfers, notifications or variations to their marketing authorizations in the context of Brexit.
The deadline for completing the survey is Feb. 9, 2018. Results will be shared with the European Commission and a summary will be published on EMA’s website.
Source: EMA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
